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In this issue of Immunity, Shan et al. (2012) explore the elimination of cells latently infected with HIV and the
potential implications for strategies to eradicate the virus from infected patients.The most recent estimates of the number
of HIV-infected patients receiving highly
active antiretroviral therapy (HAART) are
6.65 million globally in 2010 (WHO/
UNAIDS/UNICEF, 2011). AlthoughHAART
in these patients will dramatically extend
their lifespan, adverse effects, develop-
ment of resistance, and cost pose consid-
erable challenges to lifelong treatment.
HIV is not eradicated from the body by
these therapies, but rather persists in a
small, stable pool of cells termed the latent
viral reservoir (Chun et al., 1997; Finzi
et al., 1997; Wong et al., 1997). In order
to avoid the need for and risks associated
with lifelong HAART, there has beenmajor
recent focus on generating strategies to
purge latently infected cells and thereby
eradicate HIV from a given patient,
although there is considerable debate
over whether this is theoretically or practi-
cally achievable (Richman et al., 2009).
In this issueof Immunity, a studybyShan
et al. (2012) attempts to answer some
important questions related to the require-
ments for eradicating the latent reservoir.
There are several important obstacles
to the eradication of HIV from a patient.
Although estimates vary widely and the
accuracy remains uncertain, the total
number of these cells is thought to be
one to two million in a given patient
(Chun et al., 1997). Even though these
cells can be found in the peripheral blood,
their number is relatively small and neither
their precise location nor the mechanism
behind the establishment of the latency
has been fully delineated. It is unknown
whether they persist in an anatomically
privileged location such as the central
nervous system that might be less acces-
sible to pharmacologic or immunother-
apies. Althoughmany cellsmaycontribute
to the latent reservoir, the best-character-
ized latent reservoir isHIV-infected resting320 Immunity 36, March 23, 2012 ª2012 ElseCD4+ T cells. These latently infected cells
contain integrated HIV DNA but do not
produce infectious virus unless they are
stimulated or viral transcription is other-
wise induced. The majority of latently in-
fected restingCD4+T cells do not produce
viral RNAs and are refractory to therapies
that target transcription. They are also,
therefore, probably refractory to pharma-
cologic agents or immunotherapies that
target viral proteins.
There are a number of ways that scien-
tists in the field have proposed to over-
come these obstacles. Many of these
rely uponmaking the latently infected cells
transcriptionally active by stimulating
them with cytokines, through TCR stimu-
lation, or by directly inducing viral tran-
scription (Richman et al., 2009). Once viral
transcription is activated, it was consid-
ered likely that latently infected cells
would be killed by viral cytopathic effect
(CPE). Theoretically, infection of new cells
could be prevented by simultaneous
HAART. Alternatively, latently infected
cells could be activated and eliminated
by immunotherapies or the HIV-specific
CD8+ cytotoxic T lymphocyte (CTL) re-
sponse. However, whether any of these
means of elimination occurs is not com-
pletely understood. It is unknown whether
reactivation of viral transcription of latently
infected cells by agents that limit global
T cell activation results in their elimination
by CPE. In addition, the ability of HIV-
specific CD8+ T cells to eliminate reacti-
vated latently infected cells has not been
explored.
In the study by Shan et al. (2012), elimi-
nation of latently infected cells by CPE or
HIV-specific CD8+ T cells is examined.
There are considerable challenges to
studying HIV-infected latent cells in vivo
because theyarevery rare and themajority
of integrated proviruses are defective,vier Inc.further complicating interpretation of ex-
periments. Shan et al. (2012) circumvent
this challenge by using an in vitro system
where patient cells are superinfected to
explore the elimination of latently infected
cells by CPE or HIV-specific CD8+ T cells.
In this study, latently infected primary
CD4+ T cells were generated in vitro.
Chromatin remodeling enzymes such as
histone deacetylases are thought to play
an important role in the maintenance of
latency. The histone deacetylase inhibitor
suberoylanilide hydroxamic acid (SAHA),
which is an FDA-approved drug, was
shown previously to cause reactivation
in vitro of latent HIV-1 in cells from individ-
uals receivingsuppressiveHAART (Contre-
ras et al., 2009; Archin et al., 2009). In the
present study, Shan et al. (2012) made
similar observations in cells derived from
HAART recipients and also demonstrated
that virus reactivation did not cause death
of infected resting CD4+ T cells by CPE.
Furthermore, HIV-specific CD8+ T cells
failed to kill autologous, latently infected
CD4+ T cells after latent viruses were reac-
tivated.However, antigen-specific stimula-
tionofpatientCTLprior to virus reactivation
led to rapid killing of infected cells. These
results suggest that reactivation of latent
HIV-1 alone will not purge the viral latent
reservoir. Stimulation of HIV-1-specific
CD8+ T cells with cytotoxic capacity prior
to virus reactivation may be essential for
viral eradication (Figure 1).
The study raises some important
issues that remain regarding the success
of strategies for eliminating latently in-
fected cells. The first of these is whether
reactivation strategies are capable of acti-
vating all latently infected cells that can
potentially produce replication-compe-
tent virus in all anatomic compartments.
The second is whether it is possible to
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Figure 1. Purging the Latent Viral Reservoir
Early strategies employing polyclonal stimulation of latently infected CD4+ T cells with interleukin-2 (IL-2) ±
CD3 antibodies to reactivate latent HIV-1 caused substantial toxicity because of global T cell activation
and failed to eliminate the viral reservoir. Shan et al. (2012) explored the effects of the small molecule
suberoylanilide hydroxamic acid (SAHA) on latently infected primary CD4+ T cells generated in vitro to re-
activate the latent reservoir without inducing host cell activation. Virus reactivation occurred but was not
associated with death induced directly by viral proteins, i.e., viral cytopathic effect (CPE; top). Unstimu-
lated HIV-specific CD8+ cytotoxic T lymphocytes (CTLs) from patients on standard highly active antiretro-
viral therapy (HAART) also failed to efficiently kill autologous latently infected CD4+ T cells (bottom). In
contrast, antigen-specific stimulated CD8+ CTLs (depicted as a larger cell with increased intracellular
granules) kill latently infected, SAHA-reactivated cells rapidly and effectively (middle).
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Previewsof eliminating all cells producing viral gene
products. HAART results in a large decline
in the numbers of HIV-specific CD8+
T cells and is expected to diminish direct
cytotoxic capacity. In addition, most
HIV-infected patients have defects in
HIV-specific CD8+ T cell responses that
persist even in the setting of antiretrovi-
ral-induced suppression of virus replica-
tion (Migueles et al., 2008). However, it is
possible for the HIV-specific CD8+ T cell
response to control HIV replication for
25 years ormore in the absence of HAART
in patients referred to as long-term non-
progressors or elite controllers (LTNP or
EC) (Migueles et al., 2008). The HIV-
specific CD8+ T cells of these patients
have a potent ability to suppress HIV repli-
cation in vitro and have cytotoxic capac-
ities that far exceed those of progressors
(Migueles et al., 2008; Sa´ez-Cirio´n et al.,
2007). However, latently infected CD4+
T cells are not fully eradicated even in
these patients, most probably because
they are invisible to the immune system.
Attempts have beenmade to induce cyto-
toxic capacity in the HIV-specific CD8+
T cells of progressors. Restimulation of
high-level cytotoxic capacity has beenobserved in vitro only after treatment
with very potent stimuli such as phorbol
esters and calcium ionophores, which
cannot be given in vivo (Migueles et al.,
2008). Taken together, it remains unclear
how completely latently infected cells
can be stimulated to produce viral pro-
teins and how completely the CTL
response can be restored to kill those
cells in vivo.
A deeper understanding of the nature of
the latently infected pool of CD4+ T cells
and the mechanism accounting for poor
CD8+ T cell cytotoxic function is neces-
sary before eradication of HIV might be
realized in vivo. We do not completely
understand how well the generation of
latently infected cells in vitro recapitulates
the in vivo situation. In vivo, latently in-
fected CD4+ T cells or other cell types
such as macrophages may be less readily
activated or less susceptible to HIV-
specific CD8+ T cell-mediated killing. In
addition, we do not fully understand the
molecular basis of the diminished cyto-
toxic capacity of HIV-specific CD8+
T cells observed in most HIV-infected
individuals or the conditions necessary
for restimulation of full cytotoxic capacity.Immunity 3Reencounter with antigen has not been
associated with enhanced control over
virus replication subsequent to discontin-
uation of HAART. It is therefore difficult
at this time to speculate which, if any,
available therapies might most reliably
and potently restimulate an effective
CD8+ T cell cytotoxic response. Although
highly speculative, it is possible that the
concept of restimulation of viral proteins
from the latently infected pool in the face
of an effective CTL response could be
investigated in greater detail in vivo in an
animal model such as controller SIV-in-
fected rhesus macaques. In any event,
the study by Shan et al. (2012) provides
some hope that significant boosting
of CTL responses through therapeutic
vaccination or other means prior to virus
reactivation might be an effective strategy
for purging the latent pool and thereby
eradicating HIV infection.
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